Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Accumulated Expenses (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Accumulated Expenses for 9 consecutive years, with $95.0 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 4.34% to $95.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $95.0 million through Dec 2025, up 4.34% year-over-year, with the annual reading at $95.0 million for FY2025, 4.34% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $95.0 million at Denali Therapeutics, up from $4.9 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $95.0 million in Q4 2025, with the low at $4.8 million in Q3 2024.
  • Average Accumulated Expenses over 5 years is $23.1 million, with a median of $8.2 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses soared 250.77% in 2022, then plummeted 70.45% in 2024.
  • Over 5 years, Accumulated Expenses stood at $19.0 million in 2021, then skyrocketed by 250.77% to $66.7 million in 2022, then grew by 2.71% to $68.5 million in 2023, then skyrocketed by 32.95% to $91.1 million in 2024, then grew by 4.34% to $95.0 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $95.0 million, $4.9 million, and $7.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.